Design of synthetic selenopeptides with antioxidant activity for the treatment of XP and non-melanoma skin cancer
Frontiers in Systems Biology · 09.04.2026 · 6
DOI: 10.3389/fsysb.2026.1686085 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Systems Biology, online erschienen am 09.04.2026. Verfasst von Arthur Alves Coelho und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunology of Infectious Diseases, Institute of Tropical Pathology and Public Health, Universidade Federal de Goiás, Goiânia, Brazil. Die Arbeit nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Xeroderma Pigmentosum (XP) is a rare, autosomal recessive disorder characterized by extreme sensitivity to ultraviolet (UV) light. Current treatments primarily focus on symptom management and surgical tumor excisions. Selenopeptides, which possess a modified residue of Cysteine (Selenocysteine), are distinguished for their antioxidant and photoprotective properties. These properties could be beneficial in counteracting the oxidative DNA damage observed in XP lesions.
Objective
Building upon the work initiated by the Brazilian SynBio UFG iGEM Design League team, this study aimed to develop a new approach for designing and expressing synthetic selenopeptides through in silico optimization, to target both XP and non-melanoma skin cancers.
Methods
Five novel sequences of selenopeptides, named Selera, were designed and evaluated through bioinformatic tools. Selera-2 was chosen as the best model designed for its physico-chemical and structural properties and was submitted to docking analysis with therapeutic targets. Results and Discussion Docking models of B-RAF and TrxR1 demonstrated to be the most stable binding sites, considering low-binding energy levels and molecular dynamics profile, suggesting possible targets for anti tumor effect. A new recombinant expression plasmid vector was proposed, p-Sec Reg 1, in order to ensure optimal expression for future trials and production. The in silico validation of this innovative approach allows the creation of novel selenopeptides and their prospective applications in the treatment of XP and other skin cancer conditions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Immunology of Infectious Diseases, Institute of Tropical Pathology and Public Health, Universidade Federal de Goiás, Goiânia, Brazil.
- Laboratory of Genetic and Genomic, School of Agronomy, Universidade Federal de Goiás, Goiânia, Brazil.
- Laboratory of Molecular Bacteriology, Institute of Tropical Pathology and Public Health, Universidade Federal de Goiás, Goiânia, Brazil.
- Laboratory of Vaccinology, Technological Development Center, Universidade Federal de Pelotas, Pelotas, Brazil.
Zitieren
APA
Coelho, A. A., Dias, E. P. S., & Kipnis, A. (2026). Design of synthetic selenopeptides with antioxidant activity for the treatment of XP and non-melanoma skin cancer. Frontiers in Systems Biology, 6. https://doi.org/10.3389/fsysb.2026.1686085
Vancouver
Coelho AA, Dias EPS, Kipnis A. Design of synthetic selenopeptides with antioxidant activity for the treatment of XP and non-melanoma skin cancer. Frontiers in Systems Biology. 2026;6. doi:10.3389/fsysb.2026.1686085
BibTeX
@article{Coelho2026,
author = {Coelho, Arthur Alves and Dias, Eduarda Pereira Soares and Kipnis, André},
title = {Design of synthetic selenopeptides with antioxidant activity for the treatment of XP and non-melanoma skin cancer},
journal = {Frontiers in Systems Biology},
year = {2026},
volume = {6},
doi = {10.3389/fsysb.2026.1686085}
}
EUVIMED